#USA #Wayne #RBQM #CluePoints #Tufts CSDD

CluePoints and Tufts CSDD Present Groundbreaking Evidence on Financial Impact of RBQM

In a significant advancement for clinical development, CluePoints has collaborated with the Tufts Center for the Study of Drug Development (CSDD) to publish a peer-reviewed study that quantifies the financial returns associated with risk-based quality management (RBQM) methodologies. This pivotal research introduces essential data that demonstrates the economic impact of RBQM on clinical trials, ultimately bridging a long-standing gap in the industry's understanding.

Understanding RBQM in Clinical Trials

As the pharmaceutical and biotechnological sectors evolve, the requirements for regulatory compliance and operational efficiency have become increasingly critical. RBQM is a strategic framework aimed at enhancing quality oversight by utilizing data-driven techniques while also aligning with the International Council for Harmonisation's guidelines (ICH E6(R3)). Although RBQM's acceptance has grown, there has been a noticeable lack of empirical evidence supporting its financial ramifications. This new study, undertaken by experts from CluePoints and Tufts CSDD, addresses this deficiency head-on.

Research Findings and Analysis

The research authors analyzed data from 18 oncology trials carried out on CluePoints’ platform, correlating it with existing oncology benchmarks to model the financial advantages during various phases of clinical development. The study articulates two crucial metrics: 1) ROI at the trial level based on direct financial returns from RBQM due to reduced monitoring costs and shortened duration of trials, and 2) ROI at the development program level, considering risk-adjusted financial gain across extensive development pathways in oncology.

The findings highlight notable reductions in the duration of clinical phases, with time savings playing a pivotal role in economic value. Specifically:

• - RBQM-enabled trials demonstrated a decrease in clinical phase durations by 8% to 19%.
• - Financial returns were estimated at $3.2 million in phase 1 and up to $18.9 million in phase 3, showcasing ROI ratios that spanned from 6x to an impressive 23x.
• - The broader development program yielded eNPV gains ranging from $3.8 million in phase 1 to $13.8 million in phase 3, correlating to ROI multiple factors between 4x and 14x.

Time Savings as Strategic Value

The report underscores the substantial impact of time savings which emerged as the primary contributor to financial benefits. Kenneth McFarlane, VP of Strategic Consulting at CluePoints, emphasizes that this finding is crucial for sponsors, as it showcases RBQM's capacity to streamline development timelines — a strategic lever that can significantly influence overall project outcomes.

Broader Implications for RBQM

The study not only delineates the financial benefits but also outlines several overarching advantages associated with RBQM-supported oversight:

• - Enhanced data quality and oversight leading to earlier risk identification.
• - Optimized allocation and efficiency of monitoring resources.
• - Accelerated development processes, contributing to heightened overall productivity within clinical portfolios.

Abigail Dirks, MS, a Senior Data Scientist at Tufts CSDD and the primary author of the study, adds that the focus on operational and financial metrics provides a comprehensive understanding for industry stakeholders contemplating the integration of RBQM. By employing this evidence-based methodology, organizations can draw tailored insights into their portfolios, establishing a clearer business case for the adoption of RBQM practices.

Conclusion and Future Direction

The emergence of this research is not only timely but also positions RBQM as a crucial factor in the success of clinical trials. As the industry increasingly recognizes the importance of both quality and efficiency, CluePoints and Tufts CSDD’s findings will likely motivate sponsors to invest strategically in RBQM frameworks. For complete insights into the research, the full paper can be accessed in the latest edition of Therapeutic Innovation & Regulatory Science (TIRS), marking a profound step forward in the dialogue around the financial viability and operational efficiency within clinical development.

For further education on CluePoints and its innovative solutions, interested parties are encouraged to visit cluepoints.com.